JP2016532667A5 - - Google Patents

Download PDF

Info

Publication number
JP2016532667A5
JP2016532667A5 JP2016521758A JP2016521758A JP2016532667A5 JP 2016532667 A5 JP2016532667 A5 JP 2016532667A5 JP 2016521758 A JP2016521758 A JP 2016521758A JP 2016521758 A JP2016521758 A JP 2016521758A JP 2016532667 A5 JP2016532667 A5 JP 2016532667A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmaceutical combination
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016521758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016532667A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/059387 external-priority patent/WO2015054175A1/en
Publication of JP2016532667A publication Critical patent/JP2016532667A/ja
Publication of JP2016532667A5 publication Critical patent/JP2016532667A5/ja
Priority to JP2018225287A priority Critical patent/JP7403950B2/ja
Pending legal-status Critical Current

Links

JP2016521758A 2013-10-11 2014-10-07 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ Pending JP2016532667A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018225287A JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361889640P 2013-10-11 2013-10-11
US61/889,640 2013-10-11
US201361911089P 2013-12-03 2013-12-03
US61/911,089 2013-12-03
PCT/US2014/059387 WO2015054175A1 (en) 2013-10-11 2014-10-07 Combinations of histone deactylase inhibitors and immunomodulatory drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018225287A Division JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Publications (2)

Publication Number Publication Date
JP2016532667A JP2016532667A (ja) 2016-10-20
JP2016532667A5 true JP2016532667A5 (enExample) 2017-11-16

Family

ID=52810182

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016521758A Pending JP2016532667A (ja) 2013-10-11 2014-10-07 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2018225287A Active JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2021020680A Pending JP2021073314A (ja) 2013-10-11 2021-02-12 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2023184173A Pending JP2024010118A (ja) 2013-10-11 2023-10-26 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018225287A Active JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2021020680A Pending JP2021073314A (ja) 2013-10-11 2021-02-12 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2023184173A Pending JP2024010118A (ja) 2013-10-11 2023-10-26 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Country Status (17)

Country Link
US (3) US20150105358A1 (enExample)
EP (1) EP3054939A4 (enExample)
JP (4) JP2016532667A (enExample)
KR (1) KR20160060143A (enExample)
CN (1) CN105722507A (enExample)
AU (1) AU2014332147A1 (enExample)
CA (1) CA2926808A1 (enExample)
CL (1) CL2016000838A1 (enExample)
CR (1) CR20160200A (enExample)
EA (1) EA201690753A1 (enExample)
IL (1) IL244923A0 (enExample)
MX (1) MX2016004604A (enExample)
NI (1) NI201600051A (enExample)
PE (1) PE20161342A1 (enExample)
PH (1) PH12016500649A1 (enExample)
SG (1) SG11201602791RA (enExample)
WO (1) WO2015054175A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ601655A (en) 2010-01-22 2014-10-31 Acetylon Pharmaceuticals Inc Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
PL2640709T3 (pl) 2010-11-16 2016-10-31 Związki pirymidynohydroksyamidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania”
EP2839037B1 (en) 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
WO2015054099A1 (en) * 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors
ES2862126T3 (es) * 2013-10-10 2021-10-07 Acetylon Pharmaceuticals Inc Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa
KR20160060143A (ko) * 2013-10-11 2016-05-27 에이스틸론 파마수티컬스 인코포레이티드 히스톤 디아세틸라아제 억제제와 면역조절성 약물의 조합물
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
ES2806258T3 (es) 2013-12-03 2021-02-17 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
SG11201700094TA (en) 2014-07-07 2017-02-27 Acetylon Pharmaceuticals Inc Treatment of leukemia with histone deacetylase inhibitors
US9937174B2 (en) 2014-12-05 2018-04-10 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
BR112017012504A2 (pt) 2014-12-12 2018-01-09 Acetylon Pharmaceuticals, Inc. derivados de piperidina como inibidores de hdac1/2
TW201718516A (zh) 2015-06-08 2017-06-01 艾斯特隆製藥公司 組蛋白去乙醯酶抑制劑之晶形
CN107922352B (zh) 2015-06-08 2021-08-06 埃斯泰隆制药公司 制备蛋白质脱乙酰酶抑制剂的方法
WO2017143237A1 (en) * 2016-02-17 2017-08-24 Acetylon Pharmaceuticals, Inc. Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs
WO2017184774A1 (en) 2016-04-19 2017-10-26 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia
US11298354B2 (en) 2016-06-09 2022-04-12 Dana-Farber Cancer Institute, Inc. Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors
ES2929032T3 (es) 2016-08-08 2022-11-24 Acetylon Pharmaceuticals Inc Combinaciones farmacéuticas de inhibidores de histona desacetilasa 6 y anticuerpos inhibidores de CD20 y usos de los mismos
KR102002581B1 (ko) * 2016-10-04 2019-07-22 주식회사 종근당 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
EP3544612A4 (en) * 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
WO2018098168A1 (en) * 2016-11-23 2018-05-31 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof
CN114980887A (zh) 2019-12-20 2022-08-30 特纳亚治疗股份有限公司 氟代烷基-噁二唑及其用途
IL307883A (en) 2021-04-23 2023-12-01 Tenaya Therapeutics Inc HDAC6 inhibitors for use in the treatment of dilated myocardial disease
WO2022235842A1 (en) 2021-05-04 2022-11-10 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
EP2361619A1 (en) 2005-11-10 2011-08-31 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer
NZ601655A (en) * 2010-01-22 2014-10-31 Acetylon Pharmaceuticals Inc Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
PL2640709T3 (pl) * 2010-11-16 2016-10-31 Związki pirymidynohydroksyamidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania”
JP6169076B2 (ja) * 2011-07-20 2017-07-26 ザ ジェネラル ホスピタル コーポレイション 骨疾患の処置のためのヒストン脱アセチル化酵素6選択的阻害剤
KR20160060143A (ko) * 2013-10-11 2016-05-27 에이스틸론 파마수티컬스 인코포레이티드 히스톤 디아세틸라아제 억제제와 면역조절성 약물의 조합물

Similar Documents

Publication Publication Date Title
JP2017524735A5 (enExample)
JP2016536286A5 (enExample)
JP2016515561A5 (enExample)
JP2017518334A5 (enExample)
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
JP2014507446A5 (enExample)
JP2016501221A5 (enExample)
MY170656A (en) Kinase inhibitors
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
JP2015078230A5 (enExample)
EA201790088A1 (ru) Ингибиторы syk
JP2014508804A5 (enExample)
JP2016518337A5 (enExample)
JP2012144574A5 (enExample)
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
JP2013509429A5 (enExample)
FI3256218T3 (fi) Kdm1a-estäjät sairauksien hoidossa
WO2015187542A8 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
EA201691759A1 (ru) Композиции и способы лечения легочной гипертензии
EA201300862A1 (ru) Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления
PH12016500649A1 (en) Combinations of histone deactylase inhibitors and immunomodulatory drugs
WO2016004404A3 (en) Gls1 inhibitors for treating disease
JP2011088926A5 (enExample)